NYSE:CRY - Cryolife Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$29.29 -0.74 (-2.46 %)
(As of 05/19/2019 05:07 AM ET)
Previous Close$29.29
Today's Range$29.20 - $30.07
52-Week Range$23.99 - $36.05
Volume133,350 shs
Average Volume208,764 shs
Market Capitalization$1.09 billion
P/E Ratio112.65
Dividend YieldN/A
Beta0.54
CryoLife, Inc., together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser consoles, related service and maintenance, and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina. In addition, it distributes E-vita OPEN PLUS, a hybrid stent graft system for the surgical and endovascular treatment; E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac, a stent graft used to treat aneurysmal iliac arteries, as well as aneurysmal iliac side branches; E-vita THORACIC 3G, a stent graft system for the endovascular treatment of thoracic aortic aneurysms; and E-tegra, an abdominal aortic aneurysms stent graft system for the endovascular treatment. Further, the company offers vascular preservation services; and synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures. The company serves physicians, hospitals, and other healthcare industries, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

Receive CRY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP22890310
Phone770-419-3355

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$262.84 million
Cash Flow$0.7319 per share
Book Value$7.30 per share

Profitability

Net Income$-2,840,000.00

Miscellaneous

Employees1,100
Market Cap$1.09 billion
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable

Cryolife (NYSE:CRY) Frequently Asked Questions

What is Cryolife's stock symbol?

Cryolife trades on the New York Stock Exchange (NYSE) under the ticker symbol "CRY."

How were Cryolife's earnings last quarter?

Cryolife Inc (NYSE:CRY) posted its earnings results on Tuesday, April, 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.04. The medical equipment provider earned $67.50 million during the quarter, compared to analyst estimates of $66.37 million. Cryolife had a negative net margin of 0.09% and a positive return on equity of 3.79%. The business's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.02 EPS. View Cryolife's Earnings History.

When is Cryolife's next earnings date?

Cryolife is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Cryolife.

What guidance has Cryolife issued on next quarter's earnings?

Cryolife updated its FY19 earnings guidance on Tuesday, April, 30th. The company provided EPS guidance of $0.28-0.32 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.30. The company issued revenue guidance of $280-284 million, compared to the consensus revenue estimate of $282.35 million.

What price target have analysts set for CRY?

3 brokerages have issued 12-month price targets for Cryolife's shares. Their forecasts range from $29.65 to $35.00. On average, they anticipate Cryolife's share price to reach $32.2167 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Cryolife.

What is the consensus analysts' recommendation for Cryolife?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryolife in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cryolife.

What are Wall Street analysts saying about Cryolife stock?

Here are some recent quotes from research analysts about Cryolife stock:
  • 1. According to Zacks Investment Research, "CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife's BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. " (4/23/2019)
  • 2. Needham & Company LLC analysts commented, "CRY has undergone a transition into a higher growth company with two major acquisitions since 2015. We believe that it has a full pipeline including 13 new products and indications but we don’t expect these to begin to translate to stronger revenue growth until 2020. And 2019 appears to be a transition year from an earnings and margin perspective. Given all of this, and our belief that CRY shares are fairly valued, we initiate coverage with a Hold rating." (2/27/2019)
  • 3. Northland Securities analysts commented, "We continue to be strongly bullish on CryoLife. Our thesis is predicated on a few simple things: 1) Our belief in the New product intros over the next few years. The stock currently trades at ~4x Sales, which is a discount to the 5.2x multiple for the broader space. For sure, the volatility in CryoLife stock will not be as much as other players in the space. But this is a steady eddy story." (1/17/2019)

Has Cryolife been receiving favorable news coverage?

Media coverage about CRY stock has trended negative recently, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cryolife earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.

Who are some of Cryolife's key competitors?

What other stocks do shareholders of Cryolife own?

Who are Cryolife's key executives?

Cryolife's management team includes the folowing people:
  • Mr. James Patrick MacKin, Chairman, Pres & CEO (Age 52)
  • Mr. David Ashley Lee CPA, CPA, Exec. VP, COO & CFO (Age 54)
  • Ms. Jean F. Holloway, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 62)
  • Mr. John E. Davis, Sr. VP of Global Sales & Marketing (Age 54)
  • Ms. Amy D. Horton CPA, CPA, VP & Chief Accounting Officer (Age 49)

Who are Cryolife's major shareholders?

Cryolife's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.62%), Dimensional Fund Advisors LP (4.61%), Macquarie Group Ltd. (4.32%), Morgan Stanley (4.17%), ArrowMark Colorado Holdings LLC (1.48%) and William Blair Investment Management LLC (1.43%). Company insiders that own Cryolife stock include Amy Horton, C Elkins Ronald, David Ashley Lee, David C Gale, Harvey Morgan, James Benson, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Institutional Ownership Trends for Cryolife.

Which major investors are selling Cryolife stock?

CRY stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Morgan Stanley, Renaissance Technologies LLC, BlackRock Inc., Janney Montgomery Scott LLC, Parametric Portfolio Associates LLC, THB Asset Management and JPMorgan Chase & Co.. Company insiders that have sold Cryolife company stock in the last year include Amy Horton, C Elkins Ronald, David Ashley Lee, Harvey Morgan, James P Mackin, Jean F Holloway, John E Davis, Ronald D Mccall and Scott B Capps. View Insider Buying and Selling for Cryolife.

Which major investors are buying Cryolife stock?

CRY stock was purchased by a variety of institutional investors in the last quarter, including Schonfeld Strategic Advisors LLC, Wasatch Advisors Inc., William Blair Investment Management LLC, Hodges Capital Management Inc., Royce & Associates LP, SG Capital Management LLC, Elk Creek Partners LLC and Penn Capital Management Co. Inc.. View Insider Buying and Selling for Cryolife.

How do I buy shares of Cryolife?

Shares of CRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cryolife's stock price today?

One share of CRY stock can currently be purchased for approximately $29.29.

How big of a company is Cryolife?

Cryolife has a market capitalization of $1.09 billion and generates $262.84 million in revenue each year. The medical equipment provider earns $-2,840,000.00 in net income (profit) each year or $0.26 on an earnings per share basis. Cryolife employs 1,100 workers across the globe.

What is Cryolife's official website?

The official website for Cryolife is http://www.cryolife.com.

How can I contact Cryolife?

Cryolife's mailing address is 1655 Roberts Boulevard N.W, Kennesaw GA, 30144. The medical equipment provider can be reached via phone at 770-419-3355 or via email at [email protected]


MarketBeat Community Rating for Cryolife (NYSE CRY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  280 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  489
MarketBeat's community ratings are surveys of what our community members think about Cryolife and other stocks. Vote "Outperform" if you believe CRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel